Jones Trading Reiterates Buy Rating on Dyne Therapeutics (DYN): "should clinch accelerated approval in the US"
Tweet Send to a Friend
Jones Trading analyst Catherine Novack reiterated a Buy rating and $35.00 price target on Dyne Therapeutics (NASDAQ: DYN)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
